Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Therapeutic Drug Monitoring in Fungal Infections: the Dawn of Proactive Monitoring

Version 1 : Received: 21 May 2021 / Approved: 24 May 2021 / Online: 24 May 2021 (10:24:20 CEST)

How to cite: Schoenenberger-Arnaiz, J.A.; Aragones-Eroles, A.; Taberner-Bonastre, P.; Morales-Portillo, A. Therapeutic Drug Monitoring in Fungal Infections: the Dawn of Proactive Monitoring. Preprints 2021, 2021050554 (doi: 10.20944/preprints202105.0554.v1). Schoenenberger-Arnaiz, J.A.; Aragones-Eroles, A.; Taberner-Bonastre, P.; Morales-Portillo, A. Therapeutic Drug Monitoring in Fungal Infections: the Dawn of Proactive Monitoring. Preprints 2021, 2021050554 (doi: 10.20944/preprints202105.0554.v1).

Abstract

Therapeutic Drug Monitoring (TDM) is potentially a useful tool that can be employed to increase the efficacy and decrease the toxicity of antifungal drugs. The aim of this narrative review is to provide an overview of the current use of TDM in clinical practice, and to present the evidence available regarding its use in proactive clinical settings for preventing and managing treatment failure. This review also presents the existing evidence regarding the association of various clinical outcomes with specific thresholds of drug concentrations in everyday practice. Articles concerning the use of TDM of triazoles in the treatment of fungal infections were retrieved through an electronic search using PubMed. In clinical practice, TDM has an increasingly important role in the management of antifungal drugs as a consequence of the improvement in the knowledge of the pharmacokinetics and pharmacodynamics of these drugs. The currently available evidence shows a direct exposure-response relationship for triazoles, though the PK/PD profile is unpredictable. Current guidelines and treatment consensus statements recommend the proactive TDM of voriconazole, posaconazole, and itraconazole to optimize dosage regimens and improve outcomes for adult and pediatric patients.

Subject Areas

therapeutic drug monitoring; proactive; antifungal drugs

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.